S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
NASDAQ:VRCA

Verrica Pharmaceuticals Stock Forecast, Price & News

$9.26
-0.14 (-1.49%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.02
$9.76
50-Day Range
$9.19
$13.36
52-Week Range
$8.51
$18.42
Volume
87,112 shs
Average Volume
101,370 shs
Market Capitalization
$254.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.06
30 days | 90 days | 365 days | Advanced Chart
Receive VRCA News and Ratings via Email

Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Verrica Pharmaceuticals logo

About Verrica Pharmaceuticals

Verrica Pharmaceuticals, Inc. engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product candidate VP-102, is a proprietary topical therapy used in common skin indications including molluscum contagiosum and verruca vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VRCA
Fax
N/A
Employees
29
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$1.28 per share

Profitability

Net Income
$-42.69 million
Pretax Margin
-301.45%

Debt

Price-To-Earnings

Miscellaneous

Free Float
16,454,000
Market Cap
$254.83 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/12/2021
Today
12/03/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/03/2022

MarketRank

Overall MarketRank

1.89 out of 5 stars

Medical Sector

742nd out of 1,391 stocks

Pharmaceutical Preparations Industry

348th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Verrica Pharmaceuticals (NASDAQ:VRCA) Frequently Asked Questions

Is Verrica Pharmaceuticals a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Verrica Pharmaceuticals stock.
View analyst ratings for Verrica Pharmaceuticals
or view top-rated stocks.

How has Verrica Pharmaceuticals' stock price been impacted by COVID-19?

Verrica Pharmaceuticals' stock was trading at $10.52 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VRCA shares have decreased by 12.0% and is now trading at $9.26.
View which stocks have been most impacted by COVID-19
.

When is Verrica Pharmaceuticals' next earnings date?

Verrica Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Verrica Pharmaceuticals
.

How were Verrica Pharmaceuticals' earnings last quarter?

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) released its quarterly earnings data on Friday, November, 12th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.51) by $0.04.
View Verrica Pharmaceuticals' earnings history
.

What price target have analysts set for VRCA?

5 analysts have issued 12-month target prices for Verrica Pharmaceuticals' stock. Their forecasts range from $16.00 to $20.00. On average, they anticipate Verrica Pharmaceuticals' stock price to reach $18.80 in the next year. This suggests a possible upside of 103.0% from the stock's current price.
View analysts' price targets for Verrica Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Verrica Pharmaceuticals' key executives?

Verrica Pharmaceuticals' management team includes the following people:
  • Ted White, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Terry Kohler, Chief Financial & Accounting Officer
  • Gary Goldenberg, Chief Medical Officer
  • Eugene Scavola, Executive Vice President-Technical Operations
  • Christopher G. Hayes, Secretary, Chief Legal & Compliance Officer (LinkedIn Profile)

What other stocks do shareholders of Verrica Pharmaceuticals own?

When did Verrica Pharmaceuticals IPO?

(VRCA) raised $75 million in an initial public offering (IPO) on Friday, June 15th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO.

What is Verrica Pharmaceuticals' stock symbol?

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

Who are Verrica Pharmaceuticals' major shareholders?

Verrica Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.35%), Altium Capital Management LP (0.93%), Geode Capital Management LLC (0.87%), Bank of New York Mellon Corp (0.16%), MML Investors Services LLC (0.16%) and Morgan Stanley (0.16%). Company insiders that own Verrica Pharmaceuticals stock include A Brian Davis, Christopher G Hayes, Craig Ballaron, Paul B Manning and Ted White.
View institutional ownership trends for Verrica Pharmaceuticals
.

Which institutional investors are selling Verrica Pharmaceuticals stock?

VRCA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Altium Capital Management LP, Morgan Stanley, BlackRock Inc., California State Teachers Retirement System, and UBS Group AG.
View insider buying and selling activity for Verrica Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Verrica Pharmaceuticals stock?

VRCA stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, HighVista Strategies LLC, MML Investors Services LLC, Citadel Advisors LLC, Barclays PLC, Bank of New York Mellon Corp, and BNP Paribas Arbitrage SA. Company insiders that have bought Verrica Pharmaceuticals stock in the last two years include A Brian Davis, Christopher G Hayes, Craig Ballaron, Paul B Manning, and Ted White.
View insider buying and selling activity for Verrica Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Verrica Pharmaceuticals?

Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verrica Pharmaceuticals' stock price today?

One share of VRCA stock can currently be purchased for approximately $9.26.

How much money does Verrica Pharmaceuticals make?

Verrica Pharmaceuticals has a market capitalization of $254.83 million. The company earns $-42.69 million in net income (profit) each year or ($1.41) on an earnings per share basis.

How many employees does Verrica Pharmaceuticals have?

Verrica Pharmaceuticals employs 29 workers across the globe.

What is Verrica Pharmaceuticals' official website?

The official website for Verrica Pharmaceuticals is www.verrica.com.

Where are Verrica Pharmaceuticals' headquarters?

Verrica Pharmaceuticals is headquartered at 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380.

How can I contact Verrica Pharmaceuticals?

Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The company can be reached via phone at (434) 453-3300 or via email at [email protected].


This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.